Matairesinol Nanoparticles Restore Chemosensitivity and Suppress Colorectal Cancer Progression in Preclinical Models: Role of Lipid Metabolism Reprogramming
Nano Letters · 08.03.2023 · 23 (5) · 1970-1980
DOI: 10.1021/acs.nanolett.3c00035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nano Letters, online erschienen am 20.02.2023. Verfasst von Shenshen Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Capital Medical University, Beijing 100069, P.R. China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colitis. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: NIEHS NIH HHS, National Institute of Environmental Health Sciences, Beijing Municipal Commission of Education.
Abstract (Originalsprache)
Oncogenic-driven lipogenic metabolism is a common hallmark of colorectal cancer (CRC) progression. Therefore, there is an urgent need to develop novel therapeutic strategies for metabolic reprogramming. Herein, the metabolic profiles in the plasma between CRC patients and paired healthy controls were compared using metabolomics assays. Matairesinol downregulation was evident in CRC patients, and matairesinol supplementation significantly represses CRC tumorigenesis in azoxymethane/dextran sulfate sodium (AOM/DSS) colitis-associated CRC mice. Matairesinol rewired lipid metabolism to improve the therapeutic efficacy in CRC by inducing mitochondrial damage and oxidative damage and blunting ATP production. Finally, matairesinol-loaded liposomes significantly promoted the enhanced antitumor activity of 5-Fu/leucovorin combined with oxaliplatin (FOLFOX) in CDX and PDX mouse models by restoring chemosensitivity to the FOLFOX regimen. Collectively our findings highlight matairesinol-mediated lipid metabolism reprogramming as a novel druggable strategy to restore CRC chemosensitivity, and this nanoenabled approach for matairesinol will improve the chemotherapeutic efficacy with good biosafety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Public Health, Capital Medical University, Beijing 100069, P.R. China.
- Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P.R. China.
- Department of Anatomical, Histological, Medical and Legal Locomotive Apparatus, Section of Human Anatomy Via Alfonso Borelli, Sapienza University of Rome, Roma 5000161, Italia.
- Department of Anatomical, Histological, Forensic Medicine and Orthopedic Science, Sapienza University of Rome, Roma 5000161, Italia.
- Department of Molecular Pharmacology, Albert Einstein College of Medicine, Forchheimer 209, 1300 Morris Park Avenue, Bronx, New York 10461, United States.
- Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing 210009, P.R. China.
ORCID-Profile: Giuseppe Familiari, Rui Chen
Förderung
- NIEHS NIH HHS
- National Institute of Environmental Health Sciences
- Beijing Municipal Commission of Education
- National Natural Science Foundation of China
- Beijing Municipality
Zitieren
APA
Wu, S., Wang, J., Fu, Z., Familiari, G., Relucenti, M., Aschner, M., Li, X., Chen, H., & Chen, R. (2023). Matairesinol Nanoparticles Restore Chemosensitivity and Suppress Colorectal Cancer Progression in Preclinical Models: Role of Lipid Metabolism Reprogramming. Nano Letters, 23(5), 1970-1980. https://doi.org/10.1021/acs.nanolett.3c00035
Vancouver
Wu S, Wang J, Fu Z, Familiari G, Relucenti M, Aschner M, et al. Matairesinol Nanoparticles Restore Chemosensitivity and Suppress Colorectal Cancer Progression in Preclinical Models: Role of Lipid Metabolism Reprogramming. Nano Letters. 2023;23(5):1970-1980. doi:10.1021/acs.nanolett.3c00035
BibTeX
@article{Wu2023,
author = {Wu, Shenshen and Wang, Jiajia and Fu, Zan and Familiari, Giuseppe and Relucenti, Michela and Aschner, Michael and Li, Xiaobo and Chen, Hanqing and Chen, Rui},
title = {Matairesinol Nanoparticles Restore Chemosensitivity and Suppress Colorectal Cancer Progression in Preclinical Models: Role of Lipid Metabolism Reprogramming},
journal = {Nano Letters},
year = {2023},
volume = {23},
number = {5},
pages = {1970--1980},
doi = {10.1021/acs.nanolett.3c00035}
}
EUVIMED